Slide 1: Second Quarter 2018 Financial Results and Business Highlights
Second Quarter 2018 Financial Results and Business Highlights August 8, 2018
Slide 2: Forward-looking statements
Forward-looking statements “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the compa
Slide 3: Q2 2018: Progress continues towards commercialization
Q2 2018: Progress continues towards commercialization Financing • Closed $14M in registered direct offering - $24M raised in 2018 to execute growth strategy Non-GM wheat quality products: • Formed collaboration with Farmers Business Network to expand production capability • Planted production scale-
Slide 4: Building partnerships in the value chain to enable our GoodWheat strategy
Building partnerships in the value chain to enable our GoodWheat strategy • Consumer product testing with Food Companies 4 mid/ large food companies • Targeting 10 more companies in the next 12 months Consumers • Demand quality food ingredients (high fiber/ protein, low gluten, etc.) • Pay premium p
Slide 5: HB4 drought tolerant soybeans demonstrate yield improvements in 2017-18 trials
HB4 drought tolerant soybeans demonstrate yield improvements in 2017-18 trials 17 trials across 7 locations in Argentina showed positive yield increases over commercial controls • Second year of breeding trials in multiple elite lines completed Product launch plan initiated 3 • Hired Verdeca General
Slide 6: Other ag productivity traits reach important milestones on path to commercialization
Other ag productivity traits reach important milestones on path to commercialization Extended Shelf Life Tomatoes • Non-GM trait developed with Shiram Bioseed • Field trials demonstrated significant and consistent improvements in yield, firmness, shelf life and color • Commercial launch anticipated
Slide 7: Key financial results
Key financial results Second Quarter First Six Months Favorable/(Unfavorable) Favorable/(Unfavorable) 2018 2017 $ % 2018 2017 $ % Total revenues 436 991 (555) (56%) 650 2,009 (1,359) (68%) Cost of product revenues 271 116 (155) (134%) 307 222 (85) (38%) R&D expense 1,794 1,669 (125) (7%) 3,190 3,492
Slide 8: Thank you!
®D Arcadia BIOSCIENCE S